Serum interleukin-18 and nitric oxide activity in bladder carcinoma

European Cytokine Network

Volumn 14, Issue 3, 2003, Pages 163-167

  Bukan, Neslihan ^a   Sözen, Sinan ^a   Coskun, Ugur ^a,b   Sancak, Banu ^a   Günel, Nazan ^a   Bozkirli, Ibrahim ^a   Senocak, Çagri ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b Department of Urology ^*  (Turkey)

Author keywords

Bladder cancer; Interleukin 18; Nitrate; Nitric oxide; Nitrite

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 18; LACTATE DEHYDROGENASE; NITRATE; NITRIC OXIDE;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; CYSTITIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; HUMANS; INTERLEUKIN-18; MIDDLE AGED; NITRIC OXIDE; URINARY BLADDER NEOPLASMS;

EID: 0141992110     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Fukumoto H, Nishio M, Nishio K, Heike Y, Arioka H, Kurokawa H, et al. 1997. Interferon-gamma inducing factor gene transection into Lewis lung carcinoma cells reduces tumorigenicity in vivo. Jpn J. Cancer Res. 88: 501.
2. Kawabata T, Ichikura T, Majima T, Seki S, Chochi K, Takayama E, Hiraide H, Mochizuki H. 2001. Preoperative serum interleukin-18 level as a postoperative prognostic marker in patients with gastric carcinoma. Cancer 92: 2050.
3. Park CC, Morel JC, Amin MA, Connors MA, Harlow LA, Koch AE. 2000. Evidence of IL-18 as a novel angiogenic mediator. J. Immunol. 167: 1644.
4. Ohtsuki T, Micallef MJ, Kohno K, Tanimoto T, Ikeda M, Kurimoto M. 1997. Interleukin-18 enhances Fas ligand expression and induces apoptosis in Fas-expressing human myelomonocytic KG-1 cells. Anticancer Res. 17: 3253.
5. Pages F, Berger A, Henglein B, Piqueras B, Danel C, Zinzindohoue F, et al. 1999. Modulation of interleukin-18 expression in human colon carcinoma: consequences for tumor immune surveillance. Int. J. Cancer 84: 326.
6. Takubo T, Kumura T, Nakao T, Nakamae H, Aoyama Y, Nishiki S, et al. 2000. Comperative study on complete remission rate and overall survival in three groups classified based on the seum interleukin-18 level in non-Hodgkin's lymphoma patients. Acta Haematol. 104: 220.
7. Günel N, Coşkun U, Sancak B, Günel U, Hasdemir O, Bozkurt S. 2002. Clinical importance of serum interleukin-18 and nitric oxide activities in breast carcinoma patients. Cancer. 95: 663.
8. Yamanaka K, Hara I, Nagai H, Miyake H, Gohji K, Micallef MJ, et al. 1999. Synergistic antitumor effects of interleukin-12 gene transfer and systemic administration of interleukin-18 in a mouse bladder cancer model. Cancer Immunol. Immunother. 48: 297.
9. Ohshima H, Barthch H. 1994. Chronic infections and inflamatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. (Review) Mutat. Res. 305: 253.
10. Cui S, Reichner JS, Mateo RB, Albino JE. 1994. (Review) Activated murine macrophage induce apoptosis in tumour cells through nitric oxide-dependent or -independent mechanisms. Cancer Res. 54: 2462.
11. Chikano S, Sawada K, Shimoyama T, Kashiwamura SI, Sugihara A, Sekikawa K, et al. 2000. IL-18 and IL-12 induce intestinal inflamation and fatty liver in mice in an IFN-gamma dependent manner. Gut 47: 779.
12. Brennan PA, Palacios-Callender M, Zaki GA, Spedding AV, Langdon JD. 2001. Type II nitric oxide synthase (NOS2) expression correlates with lymph node status in oral squamous cell carcinoma. J. Oral. Pathol. Med. 30: 129.
13. Golab J. 2000. Interleukin 18-interferon gamma inducing factor-a novel player in tumour immunotherapy ? (Review) Cytokine 12: 332.
14. Klotz T, Bloch W, Jacobs G, Niggemann S, Engelmann U, Addicks K. 1999. Immunolocalization of inducible and constitutive nitric oxide synthases in human bladder cancer. Urology 54: 416.
15. Taniguchi M, Nagaoka K, Kunikata T, Kayano T, Yamauchi H, Nakamura S, et al. 1997. Characterization of antihuman interleukin-18 (IL-18) interferon-gamma-inducing factor (IGIF) mononclonal antibodies and their application in the measurement of human IL-18 by ELISA. J. Immunol. Methods 206: 107.
16. Green LC, Wagner DA, Glogowski J, Skipper PL, Whisnok JS, Tannenbaum SR. 1982. Analysis of nitrate, nitrite and (15N) nitrate in biological fluids. Anal. Biochem. 121: 131.
17. Bories PN, Bories C. 1995. Nitrate determination in biological fluids by an enzymatic one-step assay with nitrate reductase. Clin. Chem. 41: 904.
18. Okamura H, Nagata K, Komatsu T, Tanimoto T, Nukata Y, Tanabe F, et al. 1995. A novel costimulatory factor for g interferon induction found in livers of mice causes endotoxic shock. Infect. Immun. 63: 3966.
19. Okamura H, Tsutsui H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, et al. 1995. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378: 88.
20. Micallef MJ, Ohtsuki T, Kohno K, Tanabe F, Ushio S, Namba M, et al. 1996. Interferon-gamma-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-gamma production. Eur. J. Immunol. 26: 1647.
21. Thalmann GN, Sermier A, Rentsch C, Möhrle K, Cecchini MG, Studer UE. 2000. Urinary interleukin 8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. J. Urol. 164: 2129.
22. Catalona WJ, Chretien PB. 1973. Correlation among host immunocompetence and tumor stage, tumor grade and vascular permeation in transitional carcinoma. J. Urol. 110: 526.
23. O'Toole C, Perlmann P, Unsgaard B, Moberger G, Edsmyer F. 1972. Cellular immunity to human urinary bladder carcinoma. I. Correlation to clinical stage and radiotherapy. Int. J. Cancer 10: 77.
24. Olsson CA, Rao CN, Menzoian JO, Byrd WE. 1972. Immunologic unreactivity in bladder cancer patients. J. Urol. 107: 607.
25. Shapiro A, Ratliff TL, Kelley DR, Catolona WJ. 1984. Heightened interferon-γ production by mononuclear cells from bladder cancer patients. Cancer Res. 44: 3140.
26. Ikemoto S, Kishimoto T, Wada S, Nishio S, Maekawa M. Clinical studies on cell-mediated immunity in patients with urinary bladder carcinoma: blastogenic response, interleukin-2 production and interferon-γ production of lymphocytes. 1990. Br. J. Urol. 65: 333.
27. Bresnihan B, Roux-Lombard P, Murphy E, Kane D, FitzGerald O, Dayer JM. 2002. Serum interleukin 18 and interleukin 18 binding protein in rheumatoid arthiritis. Ann. Rheum. Dis. 61: 726.
28. Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG, Moncada S. 1995. Nitric oxide synthase activity in human breast cancer. Br. J. Cancer 72: 41.
29. Coşkun U, Ozenirler S, Sancak B, Bukan N. 2001. Serum and ascitic fluid nitrate levels in patients with cirrhosis. Clin. Chim. Acta 306: 127.
30. Langrehr JM, Murase N, Markus PM, Cai X, Neuhaus P, Schraut W, et al. 1992. Nitric oxide production in host-versus-graft and graft-versus-host reactions in the rat. J. Clin. Invest. 90: 679.